Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
16 Sep 2020
16 Sep 2020
Historique:
received:
08
01
2020
accepted:
28
06
2020
entrez:
6
5
2022
pubmed:
21
9
2020
medline:
21
9
2020
Statut:
epublish
Résumé
While elemene (ELE) can reverse tumor multidrug resistance (MDR), the mechanisms for ELE reversing MDR remain unclear. Numerous studies have suggested that the efflux functionality of ATP-binding cassette (ABC) transporters, not their quantity, is more relevant to tumor MDR. However, no appropriate methods exist for real-time detection of the intracellular drug efflux caused by ABC transporters
Identifiants
pubmed: 35514396
doi: 10.1039/d0ra00184h
pii: d0ra00184h
pmc: PMC9056898
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34928-34937Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Chem Soc Rev. 2013 Jan 21;42(2):662-76
pubmed: 23099531
Toxicol Appl Pharmacol. 2019 Jan 1;362:136-149
pubmed: 30391378
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Lett. 2016 Jan 1;370(1):153-64
pubmed: 26499806
Cancer Discov. 2015 Sep;5(9):944-59
pubmed: 26180042
Mol Imaging. 2011 Jun;10(3):215-26
pubmed: 21496450
Eur J Med Chem. 2017 Dec 15;142:271-289
pubmed: 28851502
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20801-6
pubmed: 24297888
Mol Carcinog. 2019 Jul;58(7):1118-1133
pubmed: 30834613
Science. 2018 Feb 23;359(6378):935-939
pubmed: 29472486
Sci Rep. 2017 Feb 06;7:41942
pubmed: 28165066
Clin Cancer Res. 2013 Aug 15;19(16):4359-4370
pubmed: 23794731
Med Res Rev. 2019 Jan;39(1):176-264
pubmed: 29809286
Drug Resist Updat. 2016 Jul;27:14-29
pubmed: 27449595
Mol Pharm. 2018 Feb 5;15(2):343-355
pubmed: 29300488
J Biomed Nanotechnol. 2018 Jan 1;14(1):190-197
pubmed: 29463376
Phytomedicine. 2019 Feb;53:154-162
pubmed: 30668394
Curr Pharm Des. 2016;22(30):4705-4716
pubmed: 26932159
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1702-7
pubmed: 14755051
Cancer Lett. 2019 May 1;449:237-251
pubmed: 30742940
Invest Radiol. 2013 Jun;48(6):413-21
pubmed: 23262791
Phytomedicine. 2019 Mar 01;55:269-281
pubmed: 30668439
PLoS One. 2011 Jan 24;6(1):e16007
pubmed: 21283667
Cancer Res. 2009 Jul 15;69(14):5867-75
pubmed: 19567678
Biofactors. 2018 Nov;44(6):558-569
pubmed: 30334318
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Eur J Med Chem. 2018 Nov 5;159:381-392
pubmed: 30308411
J Cancer. 2019 Jan 1;10(2):293-304
pubmed: 30719123
Eur J Pharm Sci. 2018 Jul 30;120:20-29
pubmed: 29704644
Cancer Res. 2007 Oct 1;67(19):9389-97
pubmed: 17909048
J Control Release. 2014 Sep 28;190:440-50
pubmed: 24874288
Drug Resist Updat. 2017 Jan;30:15-27
pubmed: 28363332
Int J Nanomedicine. 2018 Oct 10;13:6279-6296
pubmed: 30349250
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
Cancer Lett. 2018 May 1;421:186-198
pubmed: 29331420
Drug Resist Updat. 2017 May;32:23-46
pubmed: 29145976
Mol Imaging. 2012 Nov-Dec;11(6):499-506
pubmed: 23084250
Eur J Med Chem. 2018 Feb 25;146:157-170
pubmed: 29407947